GoodRx (NASDAQ:GDRX) Trading Up 2.8% Following Analyst Upgrade

GoodRx Holdings, Inc. (NASDAQ:GDRXGet Free Report) shares shot up 2.8% during mid-day trading on Tuesday after Barclays raised their price target on the stock from $9.00 to $10.00. Barclays currently has an overweight rating on the stock. GoodRx traded as high as $7.54 and last traded at $7.33. 438,661 shares changed hands during mid-day trading, a decline of 72% from the average session volume of 1,549,539 shares. The stock had previously closed at $7.13.

GDRX has been the subject of several other research reports. JPMorgan Chase & Co. upgraded GoodRx from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $7.00 to $10.00 in a research note on Friday, March 1st. KeyCorp raised GoodRx from a “sector weight” rating to an “overweight” rating and set a $9.00 target price for the company in a report on Wednesday, April 10th. Raymond James raised GoodRx from a “market perform” rating to an “outperform” rating and set a $10.00 target price for the company in a report on Thursday, May 16th. Leerink Partnrs reissued an “outperform” rating on shares of GoodRx in a report on Monday, February 26th. Finally, Wells Fargo & Company raised GoodRx from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $7.50 to $10.00 in a report on Monday, March 25th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

Check Out Our Latest Research Report on GoodRx

Hedge Funds Weigh In On GoodRx

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Beacon Capital Management LLC purchased a new stake in GoodRx during the 1st quarter worth approximately $28,000. California State Teachers Retirement System increased its holdings in shares of GoodRx by 5.1% in the 1st quarter. California State Teachers Retirement System now owns 70,912 shares of the company’s stock valued at $503,000 after acquiring an additional 3,444 shares during the last quarter. EntryPoint Capital LLC increased its holdings in shares of GoodRx by 165.2% in the 1st quarter. EntryPoint Capital LLC now owns 18,538 shares of the company’s stock valued at $132,000 after acquiring an additional 11,548 shares during the last quarter. Jupiter Asset Management Ltd. bought a new stake in shares of GoodRx in the 1st quarter valued at approximately $707,000. Finally, Picton Mahoney Asset Management bought a new stake in shares of GoodRx in the 1st quarter valued at approximately $3,467,000. 63.77% of the stock is owned by institutional investors and hedge funds.

GoodRx Stock Up 0.4 %

The company has a debt-to-equity ratio of 1.02, a quick ratio of 6.29 and a current ratio of 6.29. The firm has a market capitalization of $2.69 billion, a P/E ratio of -716.00, a P/E/G ratio of 3.05 and a beta of 1.37. The stock has a fifty day moving average price of $6.95 and a two-hundred day moving average price of $6.51.

GoodRx (NASDAQ:GDRXGet Free Report) last issued its quarterly earnings results on Thursday, February 29th. The company reported $0.02 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.02. The business had revenue of $196.64 million during the quarter, compared to the consensus estimate of $195.59 million. GoodRx had a positive return on equity of 3.45% and a negative net margin of 0.86%. Research analysts forecast that GoodRx Holdings, Inc. will post 0.23 EPS for the current year.

GoodRx Company Profile

(Get Free Report)

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.

Featured Stories

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.